Detroit-based Henry Ford Cancer Institute announced Aug. 14 that it has become the first to enroll a patient in an international brain cancer clinical trial that is expected to be the largest and most advanced glioblastoma-focused trial in the world.
The GBM AGILE trial is the first brain cancer trial to take an adaptive platform approach, allowing for constant updates to participants' treatment plans based on the latest information. As such, as the trial accrues more patient information, the faster each patient can receive the most promising treatments, all while their responses to a variety of treatments are continuously monitored and studied by the trial's researchers.
The study has been in development since 2015, with more than 130 clinicians, researchers, patient advocates and more from around the world contributing their expertise. The trial will expand to other patients across the U.S. this year before being made available to international investigators in 2020.
"The efficiency, speed and learning of GBM AGILE is intended to allow rapid discovery of better and better treatments for patients with glioblastoma," said Tom Mikkelsen, MD, medical director of Henry Ford Health System's precision medicine program and clinical trials office. "The era of data-driven innovation has arrived, and it's being applied to the most difficult problems in cancer therapy."
More articles on health IT:
Top 10 countries with the highest digital quality of life
US among global leaders in cybersecurity, report finds
OSU medical center tackles high false positive alerts on heart monitors